Methyltransferase-like 3 is a target for the diagnose and therapy of clear cell renal carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Clear cell renal cell carcinoma (ccRCC) often presents with metastatic disease, necessitating improved understanding of its development and treatment resistance.
• Methyltransferase-like 3 (METTL3) is a key enzyme in RNA N⁶-methyladenosine (m⁶A) modification, a crucial gene regulatory process implicated in cancer.

Purpose of the Study:

• To review the current evidence on METTL3's role in ccRCC pathogenesis, progression, and treatment resistance.
• To explore the diagnostic and therapeutic potential of METTL3 in ccRCC management.

Main Methods:

• Literature review synthesizing current research on METTL3's function in ccRCC.
• Analysis of METTL3's involvement in RNA stability, translation, tumor progression, metastasis, and chemoresistance.
• Evaluation of METTL3 as a prognostic biomarker and therapeutic target.

Main Results:

• METTL3 exhibits oncogenic activity in ccRCC by promoting tumor progression, metastasis, and chemoresistance via m⁶A-mediated RNA regulation.
• METTL3 demonstrates potential as a prognostic biomarker for ccRCC patients.
• Novel therapeutic strategies targeting METTL3, including small-molecule inhibitors and combination therapies, are emerging.

Conclusions:

• METTL3 is a critical factor in ccRCC development and progression.
• Targeting METTL3 presents a promising strategy for advancing precision medicine in ccRCC treatment.
• Further research into METTL3 inhibitors and combination therapies is warranted for effective ccRCC management.